Overview

• The Gamaleya institute’s ultra-personalized mRNA vaccine remains in preclinical testing and could be administered to select patients in coming months.
• The therapy uses mRNA to instruct immune cells to recognize and attack tumor-specific neoantigens, aiming to eradicate primary tumors and curb metastasis.
• Production is managed by Gamaleya, while clinical application protocols will be overseen by Moscow’s leading oncology centers.
• Officials have not publicly confirmed the target cancer type for initial trials, though melanoma patients have been widely cited as the likely first recipients.
• Parallel developments include Argentina’s Vaccimel melanoma vaccine in phase II and Russian research into oncolytic virus therapies.